Royalty Pharma 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Royalty Pharma reported 3rd quarter 2026 portfolio receipts of $890 million, up 9%, and royalty receipts up 9%; royalty receipts grew 12% in the first 9 months.
- For the first 9 months, portfolio receipts increased 9%, driven by Tremfya, Vorinigo, Evrysdi, and Imdeltre, which offset an approximately 5% combined headwind from Promacta and Embruvica.
- Return on invested capital was 14.3% and return on invested equity was 20.2% for the last 12 months ending in the 3rd quarter of 2026.
- Portfolio cash flow, defined as adjusted EBITDA less net interest paid, was $673 million in the quarter; the margin was around 76% in the quarter and 82% year-to-date.
- At the end of September 2026, Royalty Pharma had $514 million of cash and equivalents, $8.8 billion of investment-grade debt outstanding, and leverage of 2.7 times total debt to adjusted EBITDA, or 2.5 times on a net basis.
- The company deployed $1.6 billion of capital so far in 2026 with an announced value of $1.9 billion; it returned approximately $590 million to shareholders in the first 9 months through dividends and share repurchases.
- Royalty Pharma reported 5 successful pivotal Phase 3 trials and 9 positive regulatory events in 2026, including 6 FDA approvals and 3 FDA filings; management cited an approximately 90% success rate for development-stage investing.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2026 Earnings Conference Call. I would now like to turn the call over to George Grofik, Senior Vice President, Head of Investor Relations and Communications.
Please go ahead, sir. Good morning and good afternoon to everyone on the call.
Thank you for joining us to review Royalty Pharma's third quarter results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com. On slide two, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from these statements. We refer you to our most recent 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements.
Non-GAAP liquidity measures will be used to help you understand our financial results, and the reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website. With that, please advance to slide three. Our speakers on the call today are Pablo Legorreta, Chief Executive Officer and Chairman of the Board, Marshall Urist, EVP, Head of Research and Investments, and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights, after which Marshall will provide a portfolio update, and Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session when we'll be joined by Chris Hite, Chairman, Partnering and Investments. With that, I'd like to turn the call over to Pablo.
Thank you, George, and welcome to everyone on the call. It gives me great pleasure to report another strong quarter in 2026 as we execute towards our goal to be the premier capital allocator in life sciences with consistent compounding growth. Slide five summarizes our strong business momentum in the third quarter. Starting with the financials, we delivered 9% growth in portfolio receipts, our top line, and also in royalty receipts, which are our recurring cash flows. On a year-to-date basis, royalty receipts have grown by 12%, reflecting the strength of our diversified portfolio of high-quality royalties. We also maintained attractive returns in our business, with return on invested capital of 14.3% and return on invested equity of 20.2%. By combining strong growth and superior returns, we're confident we have a clear path to drive shareholder value creation.
Turning to capital allocation, we have deployed $1.6 billion of capital so far this year, with an announced value of $1.9 billion. Most recently, we acquired a royalty on Arcutis' ZORYVE, an approved therapy for immune diseases of the skin. We also acquired a royalty on Takeda's MIMRYLO, a potential blockbuster therapy for rare blood disorders, polycythemia vera. As we look ahead, our deal pipeline remains robust, supported by continued powerful fundamental tailwinds. Under our value-driven capital allocation framework, we also returned close to $590 million to shareholders in dividends and share repurchases in the first nine months of the year. Moving to our portfolio, we are excited to see a number of positive clinical and regulatory updates, which we expect to support our growth over the medium to long term. Our partner, Revolution Medicines, received FDA approval and a positive regulatory opinion in Europe for RASONQUE in pancreatic cancer.
Teva also received FDA approval for its schizophrenia therapy, WELTRUZA. While we were, of course, disappointed by the phase III results for Novartis' pelacarsen, the overwhelming weight of news across our portfolio was positive, with successful phase III results for Amgen's IMDELLTRA in first-line small cell lung cancer, and Pharvaris' deucrictibant XR in hereditary angioedema. We also structured the pelacarsen investment in a protective way where we will still make our money back plus a small return. As Marshall will explain later, our track record of success in development stage investing remains outstanding. Looking ahead, we are increasing our 2026 full-year guidance for the third consecutive quarter based on the excellent business momentum I just highlighted. Slide six is a slide we show every quarter. It demonstrates our consistent double-digit growth on average since our IPO.
We have delivered this impressive record year in, year out, regardless of the market backdrop. This reflects the quality of our asset selection and our unique business model. It is a track record that I believe very few companies in the healthcare space can match. With that, I will hand it over to Marshall.
Thanks, Pablo. I want to focus today on our recent royalty deals for MIMRYLO and ZORYVE and to give a broader update on our development stage portfolio. Beginning on slide eight, we recently acquired Zealand Pharma's royalty interest in Takeda's MIMRYLO for a total of $100 million. In return, Royalty Pharma is entitled to receive a 1% royalty on annual worldwide sales of up to $1.5 billion, tiering down to 0.75% above this sales threshold. We are also eligible to receive up to $23 million in milestones. MIMRYLO is an exciting first-in-class therapy for polycythemia vera, or PV, a rare chronic blood disorder. In PV, there is excessive red blood cell production, which thickens the blood, resulting in increased risk of clotting and major cardiovascular events. There is a high unmet need for new treatment options, as many patients are still reliant on frequent phlebotomy or blood draws.
MIMRYLO reduces the excessive red blood cell production, and in phase III, it demonstrated significant clinical benefit across a range of parameters, including phlebotomy burden and fatigue. Based on the compelling results, the FDA approved MIMRYLO in August 2026. Takeda has provided peak annual sales for MIMRYLO of between $1 billion and $2 billion, and we see clear blockbuster potential. Polycythemia vera is a potentially large market with a prevalence of around 155,000 patients in the U.S. alone. Based on this, we would expect to generate an unlevered IRR in the low double-digit percentage range, consistent with our target for approved products. Moving to slide nine and our latest transaction. In September, we agreed to pay AstraZeneca $100 million upfront for a 3% royalty on worldwide sales of ZORYVE.
This is an approved once-daily topical, which is marketed by Arcutis Biotherapeutics for three skin disorders: plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. ZORYVE offers an effective and safer alternative to widely used topical steroids. This represents a significant commercial opportunity for ZORYVE based on growing physician recognition of the local and long-term side effects of chronic steroid use. The scale of this opportunity is underscored by the modest penetration to date of branded non-steroidal topicals, which only represent 7% of the market. Arcutis' commercial execution has been impressive, and their message is resonating with physicians. ZORYVE is expected to grow by more than 40% in 2026 to over half a billion dollars, and we see clear blockbuster potential.
Consensus currently predicts ZORYVE's sales will reach $1.6 billion in the early part of the next decade, while Arcutis has supplied a peak sales estimate of $2.3 billion-$3 billion across ZORYVE's current indications. We expect the transaction to generate an unlevered IRR consistent with our target range for approved products. I want to move on now to our development stage pipeline. Slide 10 shows our scorecard for 2026 for key clinical and regulatory events. As Pablo noted, while the outcomes trial for pelacarsen was not successful, the transaction to acquire this royalty was structured in a protective manner. As a reminder, our $500 million funding agreement with Ionis included stable and predictable royalties in SPINRAZA, with upside from the pelacarsen royalty.
Based on the pelacarsen results, our royalty interest in SPINRAZA will revert to Ionis after we receive royalty payments of $550 million for a 1.1x return on the total amount funded. Overall, we remain pleased with the progress of our development stage portfolio in its entirety. So far in 2026, we are proud to have five successful pivotal phase III trials from our development stage therapies and nine positive regulatory events, including six FDA approvals and three FDA filings. Our overall track record for development stage investing continues to be well ahead of industry averages, with a success rate of approximately 90%. Importantly, many of the therapies shown on this slide have the potential to be truly transformative for patients, as well as highly commercially successful. Revolution Medicines' RASONQUE for pancreatic cancer and Cytokinetics' MYQORZO for non-obstructive hypertrophic cardiomyopathy are the two most obvious examples.
The year is not over yet, with the upcoming FDA regulatory decision expected later this year on GSK's neladalkib for non-small cell lung cancer and phase III results expected for Biogen's litifilimab in systemic lupus. Consequently, we feel really good about both the progress of our development stage pipeline this year, as well as the potential of the therapies we added this year to be very significant royalty contributors over the long term. Slide 11 details our development stage pipeline by year of potential launch. Here's a list of a dozen potential blockbuster launches over the coming years that can power our growth through 2030 and beyond. Importantly, all are either first in class or best in class, and all have been through our rigorous diligence process. As a result, we expect a significant proportion to reach the market successfully and deliver transformative benefits to patients.
To wrap up, we're extremely excited about our pipeline that, in aggregate, has the potential to add peak royalties of more than $1.7 billion to our top line in the future, and we expect to continue to add new and exciting therapies to our development stage pipeline in the years to come. With that, let me hand it over to Terry.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
